Skip to main content
Top
Published in: Cardiology and Therapy 2/2020

Open Access 01-12-2020 | Hepatic Encephalopathy | Original Research

In-Hospital Outcomes of Patients With Pulmonary Hypertension and Cirrhosis: A 6-Year Population Cohort Study of Over One Million Patients

Authors: Yaser Khalid, Neethi Dasu, Raja Fawad Zafar, Herman Suga, Kirti Dasu, Brian Blair

Published in: Cardiology and Therapy | Issue 2/2020

Login to get access

Abstract

Introduction

There is a paucity of data on the influence of sex, race, insurance, pulmonary hypertension-related complications, and cirrhosis-related complications on mortality, hospital length of stay (LOS), and total hospital charges. The aim of this study was to identify risk factors in a national population cohort (in the USA) admitted to hospital between 2012 and 2017.

Methods

All patients aged > 18 years with pulmonary hypertension and cirrhosis, who had been admitted to hospital between 2012 and 2017, were identified from the US Nationwide Inpatient Sample (NIS), a large publicly available all-payer inpatient care database in the USA. Multivariate regression analysis was used to estimate the odds ratios of in-hospital mortality, average length of hospital stay, and hospital charges, after adjusting for age, gender, race, primary insurance payer status, hospital type and size (number of beds), hospital region, hospital teaching status, and other demographic characteristics.

Results

Our study identified 1,111,594 patients who had been discharged from hospital from 2012 to 2017. Of these patients, 355,455 were admitted with pulmonary hypertension, with 9.8% having cirrhosis as a complication (n = 34,986). The analysis revealed that patients with both pulmonary hypertension and cirrhosis compared to patients with only pulmonary hypertension experience increased mortality, hospital LOS, total hospital charges, and pulmonary hypertension-related and cirrhosis-related complications. Independent positive predictors of mortality were Asian/Pacific Islander race and "other" insurance status (worker’s compensation; other US health benefits plans [CHAMPUS/TRICARE, CHAMPVA, Title V]). Independent positive predictors of increased hospital LOS were black race and "other" patients (more than one race/mixed). Independent positive predictors of increased total hospital charges were male gender, Hispanic ethnicity, Asian/Pacific Islander race, and other insurance status. Pulmonary hypertension-related complications (cor pulmonale, pulmonary embolism, hemoptysis, cardiac arrest, atrial fibrillation, ventricular tachycardia) and cirrhosis-related complications (ascites, hepatorenal syndrome, hepatic encephalopathy, variceal bleeding, portal hypertension) were independent positive predictors of mortality, hospital LOS, and total hospital charges.

Conclusions

Patients with pulmonary hypertension and cirrhosis have increased mortality and hospital utilization compared to patients with only pulmonary hypertension. We identified key drivers for these outcomes. Targeted interventions, such as novel medications, right-to-left shunts, more evaluations for lung transplantation, and reversal of pulmonary vacular remodeling, are needed for the subgroups identified in this study in order to improve outcomes.
Literature
2.
3.
go back to reference Hoeper MM, Ghofrani H-A, Grünig E, Klose H, Olschewski H, Rosenkranz S. Pulmonary hypertension. Dtsch Ärztebl Int. 2017;114(5):73–84.PubMed Hoeper MM, Ghofrani H-A, Grünig E, Klose H, Olschewski H, Rosenkranz S. Pulmonary hypertension. Dtsch Ärztebl Int. 2017;114(5):73–84.PubMed
4.
go back to reference Parikh KS, Stackhouse KA, Hart SA, Bashore TM, Krasuski RA. Health insurance and racial disparities in pulmonary hypertension outcomes. Am J Manag Care. 2017;23(8):474–80.PubMed Parikh KS, Stackhouse KA, Hart SA, Bashore TM, Krasuski RA. Health insurance and racial disparities in pulmonary hypertension outcomes. Am J Manag Care. 2017;23(8):474–80.PubMed
5.
go back to reference Zou B, Yeo YH, Jeong D, et al. A nationwide study of inpatient admissions, mortality, and costs for patients with cirrhosis from 2005 to 2015 in the USA. Dig Dis Sci. 2020;65(5):1520–8.CrossRefPubMed Zou B, Yeo YH, Jeong D, et al. A nationwide study of inpatient admissions, mortality, and costs for patients with cirrhosis from 2005 to 2015 in the USA. Dig Dis Sci. 2020;65(5):1520–8.CrossRefPubMed
6.
go back to reference Kim D, Cholankeril G, Li AA, et al. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005–2014. Liver Int. 2019;39(9):1661–71.CrossRefPubMed Kim D, Cholankeril G, Li AA, et al. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005–2014. Liver Int. 2019;39(9):1661–71.CrossRefPubMed
8.
go back to reference Sikachi RR, Sahni S, Mehta D, Agarwal A, Agrawal A. Nationwide trends in inpatient admissions of pulmonary hypertension in the United States from 2000 to 2013. Adv Respir Med. 2017;85(2):11.CrossRef Sikachi RR, Sahni S, Mehta D, Agarwal A, Agrawal A. Nationwide trends in inpatient admissions of pulmonary hypertension in the United States from 2000 to 2013. Adv Respir Med. 2017;85(2):11.CrossRef
9.
go back to reference Talwar A, Sahni S, Talwar A, Kohn N, Klinger JR. Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation. Pulm Circ. 2016;6(2):191–5.CrossRefPubMedPubMedCentral Talwar A, Sahni S, Talwar A, Kohn N, Klinger JR. Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation. Pulm Circ. 2016;6(2):191–5.CrossRefPubMedPubMedCentral
11.
go back to reference Medrek S, Sahay S, Zhao C, Selej M, Frost A. Impact of race on survival in pulmonary arterial hypertension: results from the REVEAL registry. J Heart Lung Transplant. 2020;39(4):321–30.CrossRefPubMed Medrek S, Sahay S, Zhao C, Selej M, Frost A. Impact of race on survival in pulmonary arterial hypertension: results from the REVEAL registry. J Heart Lung Transplant. 2020;39(4):321–30.CrossRefPubMed
12.
13.
go back to reference Lacey M, Hunsche E, Buzinec P, Drake W, Nagao M, Régulier E. Hospitalization costs related to pulmonary hypertension (PH) among medicare advantage or commercially insured patients with pulmonary arterial hypertension (PAH) in the United States. Value Health. 2013;16(3):A233.CrossRef Lacey M, Hunsche E, Buzinec P, Drake W, Nagao M, Régulier E. Hospitalization costs related to pulmonary hypertension (PH) among medicare advantage or commercially insured patients with pulmonary arterial hypertension (PAH) in the United States. Value Health. 2013;16(3):A233.CrossRef
15.
go back to reference Hoeper MM, Galiè N, Murali S, et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165(3):341–4.CrossRefPubMed Hoeper MM, Galiè N, Murali S, et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165(3):341–4.CrossRefPubMed
17.
go back to reference Jamil K, Huang X, Lovelace B, Pham AT, Lodaya K, Wan G. The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. J Med Econ. 2019;22(5):421–9.CrossRefPubMed Jamil K, Huang X, Lovelace B, Pham AT, Lodaya K, Wan G. The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. J Med Econ. 2019;22(5):421–9.CrossRefPubMed
18.
go back to reference Tapson VF, Platt DM, Xia F, et al. Monitoring for pulmonary hypertension following pulmonary embolism: the INFORM study. Am J Med. 2016;129(9):978–85.CrossRefPubMed Tapson VF, Platt DM, Xia F, et al. Monitoring for pulmonary hypertension following pulmonary embolism: the INFORM study. Am J Med. 2016;129(9):978–85.CrossRefPubMed
19.
go back to reference Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest. 1997;112(2):440–4.CrossRefPubMed Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest. 1997;112(2):440–4.CrossRefPubMed
20.
go back to reference Temple IP. Arrhythmias in pulmonary arterial hypertension. J Congenit Cardiol. 2017;1(1):2.CrossRef Temple IP. Arrhythmias in pulmonary arterial hypertension. J Congenit Cardiol. 2017;1(1):2.CrossRef
Metadata
Title
In-Hospital Outcomes of Patients With Pulmonary Hypertension and Cirrhosis: A 6-Year Population Cohort Study of Over One Million Patients
Authors
Yaser Khalid
Neethi Dasu
Raja Fawad Zafar
Herman Suga
Kirti Dasu
Brian Blair
Publication date
01-12-2020

Other articles of this Issue 2/2020

Cardiology and Therapy 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.